Form 4: Xeris Biopharma Holdings Officer Disposes of Shares to Cover Tax Obligations

Kevin McCulloch, President and COO of Xeris Biopharma Holdings, disposed of shares to cover income tax obligations related to vested Restricted Stock Units.

Summary

• On January 3, 2025, Kevin McCulloch, President and Chief Operating Officer of Xeris Biopharma Holdings, Inc., disposed of 24,501 shares of common stock to satisfy income tax obligations related to the vesting of Restricted Stock Units.
• The shares were sold at a price of $3.61 per share.
• Following the transaction, McCulloch directly owns 1,577,452 shares of Xeris Biopharma Holdings, Inc.
• McCulloch also has indirect ownership of 25,000 shares held by his spouse and 2,000 shares held by the Charles R. McCulloch Trust dated 1990, but disclaims beneficial ownership except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of a routine transaction. It doesn't indicate positive or negative sentiment about the company's prospects.

Industry Context

This is a routine Form 4 filing related to insider transactions. It is common for company executives to sell shares to cover tax obligations arising from the vesting of stock awards.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a standard procedure for covering tax obligations.

Key Dates